Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 8 studies | 23% ± 9% | |
microglial cell | 7 studies | 26% ± 7% | |
astrocyte | 7 studies | 28% ± 10% | |
macrophage | 6 studies | 33% ± 6% | |
GABAergic neuron | 4 studies | 35% ± 12% | |
glutamatergic neuron | 4 studies | 42% ± 14% | |
myeloid cell | 4 studies | 24% ± 6% | |
oligodendrocyte precursor cell | 3 studies | 22% ± 4% | |
interneuron | 3 studies | 35% ± 19% | |
oligodendrocyte | 3 studies | 20% ± 4% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 6 studies | 30% ± 11% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 2107.29 | 245 / 245 | 100% | 21.59 | 502 / 502 |
esophagus | 100% | 1610.92 | 1444 / 1445 | 100% | 11.50 | 183 / 183 |
uterus | 100% | 1968.91 | 170 / 170 | 100% | 13.38 | 458 / 459 |
brain | 100% | 1228.14 | 2635 / 2642 | 100% | 18.37 | 703 / 705 |
breast | 100% | 1541.46 | 459 / 459 | 99% | 17.88 | 1111 / 1118 |
skin | 100% | 2729.63 | 1809 / 1809 | 99% | 17.00 | 469 / 472 |
ovary | 100% | 1713.26 | 180 / 180 | 99% | 14.85 | 426 / 430 |
kidney | 100% | 1293.70 | 89 / 89 | 99% | 18.24 | 889 / 901 |
bladder | 100% | 2071.38 | 21 / 21 | 99% | 13.32 | 497 / 504 |
intestine | 100% | 1446.74 | 966 / 966 | 98% | 9.36 | 519 / 527 |
lung | 100% | 1353.43 | 576 / 578 | 99% | 12.02 | 1141 / 1155 |
stomach | 99% | 891.50 | 355 / 359 | 99% | 10.02 | 282 / 286 |
thymus | 100% | 860.32 | 650 / 653 | 96% | 9.22 | 582 / 605 |
pancreas | 95% | 545.01 | 312 / 328 | 98% | 11.74 | 175 / 178 |
adrenal gland | 100% | 1663.42 | 258 / 258 | 92% | 8.49 | 212 / 230 |
liver | 98% | 734.50 | 222 / 226 | 89% | 6.48 | 363 / 406 |
adipose | 100% | 1482.25 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 23.40 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 12.55 | 29 / 29 |
spleen | 100% | 1770.41 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 14.09 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 11.06 | 1 / 1 |
blood vessel | 100% | 1325.35 | 1334 / 1335 | 0% | 0 | 0 / 0 |
muscle | 99% | 1175.90 | 796 / 803 | 0% | 0 | 0 / 0 |
heart | 98% | 897.69 | 845 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 92% | 726.74 | 852 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0021776 | Biological process | smoothened signaling pathway involved in spinal cord motor neuron cell fate specification |
GO_0035904 | Biological process | aorta development |
GO_2000059 | Biological process | negative regulation of ubiquitin-dependent protein catabolic process |
GO_0001947 | Biological process | heart looping |
GO_0007165 | Biological process | signal transduction |
GO_0042308 | Biological process | negative regulation of protein import into nucleus |
GO_0045879 | Biological process | negative regulation of smoothened signaling pathway |
GO_0060976 | Biological process | coronary vasculature development |
GO_0003281 | Biological process | ventricular septum development |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0021775 | Biological process | smoothened signaling pathway involved in ventral spinal cord interneuron specification |
GO_0043433 | Biological process | negative regulation of DNA-binding transcription factor activity |
GO_0045668 | Biological process | negative regulation of osteoblast differentiation |
GO_0001843 | Biological process | neural tube closure |
GO_0006355 | Biological process | regulation of DNA-templated transcription |
GO_0042994 | Biological process | cytoplasmic sequestering of transcription factor |
GO_0043588 | Biological process | skin development |
GO_2001040 | Biological process | positive regulation of cellular response to drug |
GO_0007286 | Biological process | spermatid development |
GO_0005654 | Cellular component | nucleoplasm |
GO_0097542 | Cellular component | ciliary tip |
GO_1990788 | Cellular component | GLI-SUFU complex |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0097546 | Cellular component | ciliary base |
GO_0005634 | Cellular component | nucleus |
GO_0008134 | Molecular function | transcription factor binding |
GO_0019901 | Molecular function | protein kinase binding |
GO_0003714 | Molecular function | transcription corepressor activity |
GO_0008013 | Molecular function | beta-catenin binding |
GO_0005515 | Molecular function | protein binding |
Gene name | SUFU |
Protein name | Negative regulator of hedgehog signaling Suppressor of fused homolog (SUFUH) Suppressor of fused homolog |
Synonyms | UNQ650/PRO1280 |
Description | FUNCTION: Negative regulator in the hedgehog/smoothened signaling pathway . Down-regulates GLI1-mediated transactivation of target genes . Down-regulates GLI2-mediated transactivation of target genes . Part of a corepressor complex that acts on DNA-bound GLI1. May also act by linking GLI1 to BTRC and thereby targeting GLI1 to degradation by the proteasome . Sequesters GLI1, GLI2 and GLI3 in the cytoplasm, this effect is overcome by binding of STK36 to both SUFU and a GLI protein . Negative regulator of beta-catenin signaling (By similarity). Regulates the formation of either the repressor form (GLI3R) or the activator form (GLI3A) of the full-length form of GLI3 (GLI3FL) . GLI3FL is complexed with SUFU in the cytoplasm and is maintained in a neutral state . Without the Hh signal, the SUFU-GLI3 complex is recruited to cilia, leading to the efficient processing of GLI3FL into GLI3R . When Hh signaling is initiated, SUFU dissociates from GLI3FL and the latter translocates to the nucleus, where it is phosphorylated, destabilized, and converted to a transcriptional activator (GLI3A) . Required for normal embryonic development (By similarity). Required for the proper formation of hair follicles and the control of epidermal differentiation (By similarity). . FUNCTION: Negative regulator in the hedgehog signaling pathway. Down-regulates GLI1-mediated transactivation of target genes. Part of a corepressor complex that acts on DNA-bound GLI1. May also act by linking GLI1 to BTRC and thereby targeting GLI1 to degradation by the proteasome. Sequesters GLI1, GLI2 and GLI3 in the cytoplasm, this effect is overcome by binding of STK36 to both SUFU and a GLI protein. Negative regulator of beta-catenin signaling. Regulates the formation of either the repressor form (GLI3R) or the activator form (GLI3A) of the full-length form of GLI3 (GLI3FL). GLI3FL is complexed with SUFU in the cytoplasm and is maintained in a neutral state. Without the Hh signal, the SUFU-GLI3 complex is recruited to cilia, leading to the efficient processing of GLI3FL into GLI3R. When Hh signaling is initiated, SUFU dissociates from GLI3FL and the latter translocates to the nucleus, where it is phosphorylated, destabilized, and converted to a transcriptional activator (GLI3A). . |
Accessions | A0A6M5WQ99 ENST00000369902.8 [Q9UMX1-1] A0A223LX15 Q9UMX1 ENST00000369899.6 [Q9UMX1-2] ENST00000423559.2 [Q9UMX1-3] |